Bafna Pharmaceuticals Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bafna Pharmaceuticals Ltd. on BSE

Load latest

Bafna Pharmaceuticals Ltd.

29 May 2024

111.54

5.00%

Result

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held …

BSE India

The Board of Directors in the meeting held on 29/05/2019 has inter-alia (i) approved the audited financial results of the Company for the quarter & year ended March 31, 2024; (ii) ii). Appointment of Mr. A. Mohanachandran, as the Company Secretary & Compliance Officer of the Company with effect from May 29, 2024

pdf

Bafna Pharmaceuticals Ltd.

29 May 2024

111.54

5.00%

Result

BAFNA PHARMACEUTICALS LTD. - 532989 - Audited Financial Results Of The Company For The Quarter & …

BSE India

We are herewith submitting the Audited Financial Results for the Quarter & Year ended 31/03/2024

pdf

Bafna Pharmaceuticals Ltd.

22 May 2024

111.54

5.00%

Board Meeting

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Consideration And Approval Of The Audited …

BSE India

BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 ,inter alia, to consider and approve Consideration and Approval of the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2024.

pdf

Bafna Pharmaceuticals Ltd.

26 Apr 2024

111.54

5.00%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement Regarding Inauguration Of New Quality Control Laboratory Of Company

BSE India

We are delighted to announce the inauguration of new State-of-the-Art Quality Control Laboratory of the Company.

pdf

Bafna Pharmaceuticals Ltd.

24 Apr 2024

111.54

5.00%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 …

BSE India

We are herewith submitting the Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the period ended 31st March, 2024.

pdf

Bafna Pharmaceuticals Ltd.

23 Apr 2024

111.54

5.00%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance …

BSE India

We hereby inform that Mr. Vishnu Vasudeva Kuppa has resigned from the position of Company Secretary & Compliance officer of the Company with effect from 23rd April, 2024.

pdf

Bafna Pharmaceuticals Ltd.

22 Apr 2024

111.54

5.00%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations …

BSE India

We are herewith enclosing the Compliance Certificate issued under Regulation 40(9) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2024.

pdf

Bafna Pharmaceuticals Ltd.

15 Apr 2024

111.54

5.00%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

We are herewith enclosing Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for Quarter ended 31st March, 2024.

pdf

Bafna Pharmaceuticals Ltd.

25 Mar 2024

111.54

5.00%

SAST

BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window

BSE India

The Trading Window for the designated persons, connected persons, shall remain closed from Sunday, March 31, 2024, up to 48 hours after the declaration of Financial results of the Company by the Board of directors for the quarter and year ending March 31, 2024.

pdf

Bafna Pharmaceuticals Ltd.

14 Feb 2024

111.54

5.00%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

we have furnished herewith newspaper clippings of Un-audited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2023, which was approved by the Board in its meeting held on February 12, 2024, and published in the newspapers, namely in Makkal Kural (Tamil edition) and Business Standard (English edition) on Tuesday, February 13, 2024.

pdf

Is Bafna Pharmaceuticals Ltd. worth buying?

24 Votes:

Buy 66.67%

Sell 25.0%

Hold 8.33%